Israel Active

The AI-powered exercise platform of Israel’s Kemtai (see previously) has been selected by Israel’s Sheba Medical Center for physical therapy to soldiers injured in Gaza. Sheba also selected Israel’s COGNIshine (see previously) for cognitive, emotional and speech therapy.

A smart wound patch developed at Haifa’s Rambam Medical Center and Israel’s Noyad Biomed at Kibbutz Lavi, protects those suffering wounds that have lost blood. The patch (called Rescue Heat) warms up to 42 degrees centigrade, to protect the patient from hypothermia.

Hundreds of Israelis who suffered burn wounds on Oct 7 have been treated with pineapple stem based NexoBrid gel from Israel’s MediWound (see previously). It contains the enzyme bromelain which breaks down dead tissue in 4 hours, while preserving healthy tissue.

A patient with advanced hepatocellular carcinoma (liver cancer) who participated in the Phase II trials of namodenoson from Israel’s Can-Fite (see previously) had an extremely good response. His liver function returned to normal, and he is looking forward to a good quality of life.

The LibAirty compression vest from Israel’s Synchrony Medical (see previously) has begun clinical (human) trials at the National Cystic Fibrosis Center of Sheba Medical Center, where it was developed. Synchrony’s CEO says the device is twice as effective as similar products currently on the market.

Israel’s Skip Therapeutics is partnering with Sheba Medical Center to develop ASO-based (short RNA sequences) treatments for rare genetic diseases. Skip's ASOs (Antisense Oligonucleotide) aim to restore the function of mutated genes in genetic disorders.

Israel’s Amorphical (see previously) has adapted its amorphous calcium carbonate production technology to treat inflammatory diseases such as Crohn’s disease, multiple sclerosis, and arthritis. The mineral neutralizes the acidity within affected tissue to prevent inflammation.

Scientists at the Hebrew University of Jerusalem have discovered how DNA methylation acts as a gene control system, like a traffic light that can modulate gene activity and trigger or prevent cancer mutations. It will help develop personalized therapies for cancer patients.

Israel’s Epitomee has completed clinical trials of its ingestible pill that opens up in the stomach to produce a feeling of satiety. In 24 weeks the 140 participants who swallowed the pill lost up to 15% of their body weight, with no side effects.  Epitomee intends to apply for FDA approval in 2024.

Israel’s Exosomm extracts tiny capsules of microRNA called exosommes from cows’ milk. They then add them as a powder to food as a treatment for colitis and Crohn’s. Successful laboratory trials have led to recruitment for clinical trials at Hadassah Medical Center in Jerusalem.